Valuation
- Market cap
- 4,408,000
- Revenue TTM
- $0
- Net income TTM
- $-12,560,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 28,300
- Avg volume
- 96,362
- Day's range
- $1.33 – $1.39
- Shares out
- 3,314,000
- Stochastic %K
- 8%
- Beta
- 0.93
- Analysts
- Strong Buy
- Price target
- $45.00
Company profile
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed...
Show more
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 604 669 7207
- Website
- https://www.inmedpharma.com
- Address
- 500 West Georgia Street, Suite 1800, Vancouver, Canada
Latest news
No headlines yet.
